EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Emergent BioSolutions's Enterprise Value is $848 Mil.
Emergent BioSolutions's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-644 Mil. Therefore, Emergent BioSolutions's EV-to-EBIT for today is -1.32.
The historical rank and industry rank for Emergent BioSolutions's EV-to-EBIT or its related term are showing as below:
EBS'
s EV-to-EBIT Range Over the Past 10 Years
Min: -35512.2 Med: 13.85 Max: 80.28
Current: -1.32
During the past 13 years, the highest EV-to-EBIT of Emergent BioSolutions was 80.28. The lowest was -35512.20. And the median was 13.85.
EBS's EV-to-EBIT is ranked worse than 100% of 668
companies
in the Drug Manufacturers industry
Industry Median: 17.04
vs EBS: -1.32
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Emergent BioSolutions's Enterprise Value for the quarter that ended in Dec. 2023 was $874 Mil.
Emergent BioSolutions's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-644 Mil. Emergent BioSolutions's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -73.68%.
Emergent BioSolutions EV-to-EBIT Historical Data
The historical data trend for Emergent BioSolutions's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Emergent BioSolutions Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBIT
29.64
11.31
7.39
-7.46
-1.36
Emergent BioSolutions Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBIT
-7.46
-4.58
-2.53
-1.44
-1.36
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions EV-to-EBIT Distribution
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's EV-to-EBIT falls into.
Emergent BioSolutions EV-to-EBIT Calculation
Emergent BioSolutions's EV-to-EBIT for today is calculated as:
Emergent BioSolutions's current Enterprise Value is $848 Mil.
Emergent BioSolutions's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-644 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Emergent BioSolutions's Enterprise Value for the quarter that ended in Dec. 2023 was $874 Mil.
Emergent BioSolutions's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-644 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Emergent BioSolutions's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Emergent BioSolutions (Emergent BioSolutions) Business Description
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EBS has been successfully added to your 